Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:administered_by |
injection
|
| gptkbp:administration_schedule |
varies by vaccine type
|
| gptkbp:associated_with |
vaccine hesitancy
|
| gptkbp:benefits |
long-lasting immunity
fewer doses required risk of reversion to virulence |
| gptkbp:can_be_administered_to |
travelers
healthy individuals |
| gptkbp:can_be_administered_with |
adjuvants
|
| gptkbp:can_be_combined_with |
other vaccines
|
| gptkbp:can_cause |
mild symptoms
|
| gptkbp:clinical_trial |
conducted for new formulations
|
| gptkbp:community_health |
significant reduction in disease incidence
|
| gptkbp:contains |
weakened virus
|
| gptkbp:contraindication |
pregnant women
immunocompromised individuals |
| gptkbp:development |
derived from wild-type viruses
|
| gptkbp:duration_of_immunity |
years to decades
|
| gptkbp:example |
gptkb:MMR_vaccine
gptkb:varicella_vaccine |
| gptkbp:historical_use |
gptkb:yellow_fever_vaccine
polio vaccine measles vaccine rubella vaccine smallpox vaccine |
| https://www.w3.org/2000/01/rdf-schema#label |
modified live virus vaccine
|
| gptkbp:influences |
herd immunity
vaccine policy |
| gptkbp:investment |
mild side effects
rare severe reactions |
| gptkbp:is_compared_to |
inactivated vaccines
|
| gptkbp:is_effective_against |
certain diseases
|
| gptkbp:mechanism_of_action |
stimulates immune system
|
| gptkbp:produces |
immune response
|
| gptkbp:regulatory_compliance |
FDA approved
|
| gptkbp:requires |
informed consent
booster doses in some cases trained healthcare personnel for administration |
| gptkbp:research |
ongoing for new vaccines
|
| gptkbp:storage |
refrigeration
lyophilized form |
| gptkbp:suitable_for |
certain chronic diseases
|
| gptkbp:type |
live attenuated vaccine
|
| gptkbp:used_for |
immunization
|
| gptkbp:used_in |
gptkb:children
adults |
| gptkbp:bfsParent |
gptkb:Equine_arteritis_virus
|
| gptkbp:bfsLayer |
6
|